NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Evaluation of HIV-activating UV doses in the skin exposed to phototherapy and photochemotherapy.

Zmudzka BZ, Miller SA, Lightfoote MM, Jacobs ME, Beer JZ; International Conference on AIDS.

Int Conf AIDS. 1996 Jul 7-12; 11: 28 (abstract no. LB.B.6029).

FDA, Rockville, MD. Fax: (301) 594-6775. E-mail: bzz@fda.dr.gov.

Objective: To evaluate the possibility of HIV activation in the skin treated with phototherapy (UVB therapy) or photochemotherapy (PUVA therapy). Methods: Using the data for HIV promoter activation in vitro, we computed UVB and PUVA doses that produce 50% of the maximal promoter activation (AD(50)). Then, using (a) literature data for UV transmittance in the human skin, (b) a composite action spectrum for HIV promoter and pyrimidine dimer induction by UVB, and c) an action spectrum for DNA synthesis inhibition by PUVA, we estimated the distribution of UVB and PUVA doses in normal type II skin. This allowed us to estimate the depth in the skin where the HIV promoter may be induced by therapeutic UVB or PUVA doses. Results: When the incident UVB dose on the surface of the skin is 5,000 J/m(2) (290-320 nm) (advanced stage UVB therapy), the dose producing 50% of the maximal HIV promoter activation (AD(50)(UVB)) may be delivered as far as the living cells of the epidermis and even to some parts of the upper dermis. When the incident UVA dose is 100 KJ/m(2) (320-400 nm) (advanced stage of PUVA therapy), and the 8-methoxypsoralen concentration in the blood is 0.1 microgram/mL (desired level), the combined PUVA doses to the mid epidermis are well below the 50% HIV promoter-activating PUVA dose (AD (50) (PUVA)). Conclusions: This analysis suggests that HIV-activating doses penetrate deeper into the skin during UVB therapy as compared with PUVA therapy. However, to provide a definitive comparison of the UVB and PUVA effects, this evaluation should be expanded to account for the complexity of the phenomena induced by UV in the skin (in particular, for the UV-induced immunomodulation and related reactions).

Publication Types:
  • Meeting Abstracts
Keywords:
  • AIDS Vaccines
  • HIV
  • Humans
  • In Vitro
  • Methoxsalen
  • PUVA Therapy
  • Photochemotherapy
  • Phototherapy
  • Skin
  • Ultraviolet Rays
  • methods
  • organization & administration
Other ID:
  • 97926905
UI: 102225478

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov